31883-05-3 Usage
Uses
Used in Pharmaceutical Industry:
CARBAMIC ACID, [10-[3-(4-MORPHOLINYL)-1-OXOPROPYL]-10H-PHENOTHIAZIN-2-YL]-, ETHYL ESTER is used as an antiarrhythmic agent for the treatment of malignant ventricular arrhythmias. It is particularly effective in suppressing premature ventricular contractions, couplets, and nonsustained ventricular tachycardia. As a class IC antiarrhythmic agent, it works by blocking the Na+ channel, which helps in stabilizing the heart rhythm and preventing life-threatening arrhythmias.
Used in Cardiac Applications:
In the field of cardiology, CARBAMIC ACID, [10-[3-(4-MORPHOLINYL)-1-OXOPROPYL]-10H-PHENOTHIAZIN-2-YL]-, ETHYL ESTER is used as a cardiac depressant with anti-arrhythmic properties. It helps in managing and treating life-threatening ventricular arrhythmias by targeting the Na+ channels in the heart, thus providing a therapeutic option for patients suffering from these conditions.
Brand Name:
Ethmozine (Roberts Pharmaceutical) is the brand name under which CARBAMIC ACID, [10-[3-(4-MORPHOLINYL)-1-OXOPROPYL]-10H-PHENOTHIAZIN-2-YL]-, ETHYL ESTER is marketed and distributed for medical use.
Originator
Ethmozine,Bristol-Myers Squibb
Therapeutic Function
Antiarrhythmic
Clinical Use
Moricizine (Ethmozine) is an antiarrhythmic used to
treat documented life-threatening arrhythmias.
Moricizine is indicated for the treatment of documented
ventricular arrhythmias, particularly sustained ventricular
tachycardia. Moricizine was evaluated in the CAST
II clinical trial for the prevention of postinfarction ventricular
premature complexes. It was ineffective and
found to be proarrhythmic. Patients in the moricizine
arm of the trial exhibited a greater incidence of sudden
cardiac death than did controls.
Side effects
The principal adverse gastrointestinal effect of moricizine
is nausea (7%). Abdominal discomfort has also
been reported. Dizziness (11%) is the most frequently
reported CNS-related adverse effect. Such reactions
increase in frequency with prolonged drug administration.
As with other antiarrhythmic drugs, moricizine has
proarrhythmic activity, which may manifest as new ventricular
ectopic beats or a worsening of preexisting ventricular
arrhythmias. These effects are most common in
patients with depressed left ventricular function and a
history of congestive heart failure. Cardiovascular effects requiring drug withdrawal include conduction defects,
sinus pauses, junctional rhythm, and A-V block.
Drug interactions
Clinically significant interactions with moricizine do not
appear to exist.
Precautions
Patients with preexisting second- or third-degree A-V
block, cardiogenic shock, or drug hypersensitivity should
not be treated with moricizine.
Check Digit Verification of cas no
The CAS Registry Mumber 31883-05-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,8,8 and 3 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 31883-05:
(7*3)+(6*1)+(5*8)+(4*8)+(3*3)+(2*0)+(1*5)=113
113 % 10 = 3
So 31883-05-3 is a valid CAS Registry Number.
InChI:InChI=1/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)
